Inventiva (IVA) Non-Current Debt (2018 - 2025)
Inventiva (IVA) posted quarterly Non-Current Debt of $58.4 billion for Q2 2025, up 115678.89% year-over-year from N/an in Q2 2024, and up 12.79% quarter-over-quarter from $51.8 billion in Q4 2024.
Analysis
Inventiva (IVA) Non-Current Debt (2018 - 2025) Analysis & Trends
Inventiva's Non-Current Debt history runs 8 years deep, the most recent figure standing at $58.4 billion for Q2 2025.
- In Q2 2025, Non-Current Debt rose 115678.89% year-over-year to $58.4 billion; the TTM figure through Jun 2025 stood at $58.4 billion (up 115678.89% YoY), while the FY2024 annual figure was $51.8 billion, up 88893.02% from the prior year.
- Non-Current Debt for Q2 2025 stood at $58.4 billion, up from $51.8 billion in the prior quarter.
- The five-year high for Non-Current Debt was $58.4 billion in Q2 2025, with the low at $10.1 million in Q4 2021.
- The 5-year median for Non-Current Debt is $47.9 million (2022), against an average of $12.5 billion.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt soared 118026.67% in 2022, then sank 99.76% in 2023.
- Inventiva's Non-Current Debt stood at $10.1 million in 2021, then jumped by 347.99% to $45.3 million in 2022, then gained by 28.48% to $58.2 million in 2023, then soared by 88893.02% to $51.8 billion in 2024, then advanced by 12.79% to $58.4 billion in 2025.
- Business Quant data shows IVA's Non-Current Debt at $58.4 billion in Q2 2025, $51.8 billion in Q4 2024, and $50.4 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - | 32.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 32.07 Mn |
| Jun 30, 2025 | 58.41 Mn |
| Dec 31, 2024 | 51.78 Mn |
| Jun 30, 2024 | 50.45 Mn |
| Dec 31, 2023 | 34.62 Mn |
| Jun 30, 2023 | 33.77 Mn |
| Dec 31, 2022 | 29.24 Mn |
| Jun 30, 2022 | 14.34 Mn |
| Dec 31, 2021 | 10.11 Mn |
| Jun 30, 2021 | 12.14 Mn |
| Mar 31, 2021 | 12.15 Mn |
| Dec 31, 2020 | 11.97 Mn |
| Dec 31, 2019 | 2,213.78 |
| Dec 31, 2018 | 84,463.34 |